Evidence map›Paper›PMID 31498409›Full record

ArticleJournal of the National Cancer Institute2020

The IARC Monographs: Updated Procedures for Modern and Transparent Evidence Synthesis in Cancer Hazard Identification.

Jonathan M Samet, Weihsueh A Chiu, Vincent Cogliano, Jennifer Jinot, David Kriebel, Ruth M Lunn, Frederick A Beland, Lisa Bero, Patience Browne, Lin Fritschi and 26 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Jonathan M SametColorado School of Public Health, CO.
Weihsueh A ChiuDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX.
Vincent CoglianoNational Center for Environmental Assessment, US Environmental Protection Agency.
Jennifer JinotNational Center for Environmental Assessment, US Environmental Protection Agency.
David KriebelDepartment of Public Health, University of Massachusetts Lowell.
Ruth M LunnNational Toxicology Program, National Institute of Environmental Health Sciences.
Frederick A BelandDivision of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR.
Lisa BeroFaculty of Medicine and Health, The University of Sydney, Australia.
Patience BrowneEnvironmental Directorate, Organisation for Economic Co-operation and Development, France.
Lin FritschiSchool of Public Health, Curtin University, Australia.
Jun KannoJapan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Japan.
Dirk W LachenmeierChemical and Veterinary Investigation Agency Karlsruhe, Germany.
Qing LanDivision of Cancer Epidemiology and Genetics, National Cancer Institute.
Gérard LasfarguesScience for Expertise Division, French Agency for Food, Environmental and Occupational Health & Safety, France.
Frank Le CurieuxEvaluation Directorate, European Chemicals Agency, Finland.
Susan PetersInstitute for Risk Assessment Sciences, Utrecht University, the Netherlands.
Pamela ShubatEnvironmental Health Division, Minnesota Department of Health.
Hideko SoneNational Institute for Environmental Studies, Yokohama University of Pharmacy, Japan.
Mary C WhiteDivision of Cancer Prevention and Control, US Centers for Disease Control and Prevention.
Jon WilliamsonDepartment of Philosophy, University of Kent, UK.
Marianna YakubovskayaMinistry of Health, Russian Federation.
Jack SiemiatyckiSchool of Public Health, University of Montreal, Canada.
Paul A WhiteEnvironmental Health Sciences and Research Bureau, Health Canada, Canada.
Kathryn Z GuytonInternational Agency for Research on Cancer, Lyon, France.
Mary K Schubauer-BeriganInternational Agency for Research on Cancer, Lyon, France.
Amy L HallInternational Agency for Research on Cancer, Lyon, France.
Yann GrosseInternational Agency for Research on Cancer, Lyon, France.
Véronique BouvardInternational Agency for Research on Cancer, Lyon, France.
Lamia Benbrahim-TallaaInternational Agency for Research on Cancer, Lyon, France.
Fatiha El GhissassiInternational Agency for Research on Cancer, Lyon, France.
Béatrice Lauby-SecretanInternational Agency for Research on Cancer, Lyon, France.
Bruce ArmstrongInternational Agency for Research on Cancer, Lyon, France.
Rodolfo SaracciInternational Agency for Research on Cancer, Lyon, France.
Jiri ZavadilInternational Agency for Research on Cancer, Lyon, France.
Kurt StraifInternational Agency for Research on Cancer, Lyon, France.
Christopher P WildInternational Agency for Research on Cancer, Lyon, France.

Funding

Molecular Epidemiology Studies of Occupational and Environmental ExposuresZIACP010121 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ROTHMAN, NATHANIEL · 2009 to 2025
$23.5M
Integrated Health Assessments for the Division of the National Toxicology ProgramZICES103317 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ROONEY, ANDREW · 2020 to 2021
$9.6M
Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

The Monographs produced by the International Agency for Research on Cancer (IARC) apply rigorous procedures for the scientific review and evaluation of carcinogenic hazards by independent experts. The Preamble to the IARC Monographs, which outlines these procedures, was updated in 2019, following recommendations of a 2018 expert advisory group. This article presents the key features of the updated Preamble, a major milestone that will enable IARC to take advantage of recent scientific and procedural advances made during the 12 years since the last Preamble amendments. The updated Preamble formalizes important developments already being pioneered in the Monographs program. These developments were taken forward in a clarified and strengthened process for identifying, reviewing, evaluating, and integrating evidence to identify causes of human cancer. The advancements adopted include the strengthening of systematic review methodologies; greater emphasis on mechanistic evidence, based on key characteristics of carcinogens; greater consideration of quality and informativeness in the critical evaluation of epidemiological studies, including their exposure assessment methods; improved harmonization of evaluation criteria for the different evidence streams; and a single-step process of integrating evidence on cancer in humans, cancer in experimental animals, and mechanisms for reaching overall evaluations. In all, the updated Preamble underpins a stronger and more transparent method for the identification of carcinogenic hazards, the essential first step in cancer prevention.

Indexed as

AnimalsCarcinogensHumansInternational AgenciesMotivationNeoplasmsProgram EvaluationPublic Health SurveillanceCarcinogens

Identifiers

PMID31498409
PMCPMC6968684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.